Verition Fund Management
BMY.RT

Verition Fund Management’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Verition Fund Management’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-124,872
Closed -$86K – 1956
2020
Q4 		$86K Sell
124,872
-70,200
-36% -$150K ﹤0.01% 1025
2020
Q3 		$439K Buy
+195,072
New +$557K 0.01% 619
2020
Q1 		– Sell
-405,872
Closed -$1.22M – 1189
2019
Q4 		$1.22M Buy
+405,872
New +$1.06M 0.02% 389

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.61B AUM 22.15% 1-Year Est. Return
WAM
Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

Verition Fund Management's BMY.RT Position: Q1 2021 in Review

Verition Fund Management sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 124,872 shares — an estimated $86K sold.

Verition Fund Management first reported a position in BMY.RT in Q4 2019 and held it in 3 quarters. The position peaked at $1.22M in Q4 2019. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • Verition Fund Management reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • Verition Fund Management sold 124,872 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $86K.
  • Verition Fund Management first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 3 quarters.
  • Verition Fund Management's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $1.22M in Q4 2019.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Verition Fund Management's 13F filing for Q1 2021, filed 18 May 2021.